FDA conducts Jan. 29 inspection of BioLife Plasma Services L. P. in Villa Park
By Y. S. Wenger
The Food and Drug Administration inspected BioLife Plasma Services L. P. in Villa Park on Jan. 29, targeting blood and blood products, according to information published on the FDA's website.
The inspection’s final report found that BioLife Plasma Services L. P. did not require corrective action to its management practices.
The FDA regularly inspects facilities nationwide to verify that workplaces and products meet FDA laws and standards designed to protect public health. The results of these inspections are made publicly available.
Its website notes that the FDA is a federal agency overseeing the safety and quality of human and animal drugs, biological products, medical devices and tobacco goods.
Information for this article is sourced from the U.S. Food and Drug Administration. Access the FDA's source data here.